Tamoxifen (Synonyms: 他莫昔芬; ICI 47699; (Z)-Tamoxifen; trans-Tamoxifen)

目录号: HY-13757A 纯度: 99.78%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

Tamoxifen (ICI 47699) 是一种口服有效的，选择性雌激素受体 (estrogen receptor) 调节剂 (SERM)，可阻断乳腺细胞中的雌激素作用，并可激活其他细胞，如骨骼，肝脏和子宫细胞中的雌激素活性。Tamoxifen 是一种有效的 Hsp90 激活剂，可增强 Hsp90 分子伴侣 ATPase 的活性。Tamoxifen 还可以有效抑制传染性 EBOV Zaire 和 Marburg (MARV)，IC₅₀ 分别为 0.1 μM 和 1.8 μM。Tamoxifen 可以激活自噬 (autophagy)，诱导凋亡 (apoptosis)。Tamoxifen 还可以诱导 CreER(T2) 转基因小鼠的基因敲除。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Tamoxifen Chemical Structure

CAS No. : 10540-29-1

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥550	In-stock
100 mg	￥190	In-stock
200 mg	￥300	In-stock
500 mg	￥500	In-stock
1 g	￥690	In-stock
5 g	￥2750	In-stock
10 g	￥3500	In-stock
50 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Tamoxifen:

MCE 顾客使用本产品发表的 119 篇科研文献

: Tamoxifen purchased from MCE. Usage Cited in: Redox Biol. 18 October 2022, 102509.; Expression of TFRC in primary fibroblasts from TFRCflox/flox and TFRC−/− mice was assessed by western blot after 5 days of Tamoxifen intraperitoneal injection and 7 days of waiting.

: Tamoxifen purchased from MCE. Usage Cited in: Clin Transl Med. 2020 Jan;10(1):137-150. [Abstract]; Different transmission of MAPK8/FoxO signaling pathway in breast cancer cells (MCF-7, T47D, ZR-75, and MDA-MB-231) and liver cells (LO2) exposed to TAM (Tamoxifen).

: Tamoxifen purchased from MCE. Usage Cited in: Cell Commun Signal. 2019 May 23;17(1):50. [Abstract]; Tamoxifen inhibits the growth and metastasis of prostate tumors in vivo. Western blot analysis of the indicated proteins in prostate primary tumors tissues.

Tamoxifen 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Estrogen Receptor/ERR 亚型特异性产品:

查看所有亚型

Estrogen receptor ERα ERβ ERRα ERRβ ERRγ

查看 HSP 亚型特异性产品:

查看所有亚型

HSP40 HSP70 HSP90 HSP105 HSF1 HSP HSPA5

生物活性
纯度 & 产品资料
参考文献

生物活性

Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells^[1]^[2]^[3]. Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC₅₀ of 0.1 μM and 1.8 μM, respectively^[5]. Tamoxifen activates autophagy and induces apoptosis^[4]. Tamoxifen also can induce gene knockout of CreER(T2) transgenic mouse^[6].

IC₅₀ & Target^[1]^[4]

Estrogen receptor

HSP90

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
518A2	IC₅₀	7.62 μM Compound: 2	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 22749392]
A2058	EC₅₀	12.5 μM Compound: TAM	Antiproliferative activity against human A2058 cells assessed as reduction in cell viability measured after 24 hrs by celltiter-blue assay Antiproliferative activity against human A2058 cells assessed as reduction in cell viability measured after 24 hrs by celltiter-blue assay	[PMID: 31099568]
A253 cell line	IC₅₀	8.92 μM Compound: 2	Cytotoxicity against human A253 cells after 96 hrs by SRB assay Cytotoxicity against human A253 cells after 96 hrs by SRB assay	[PMID: 22749392]
A2780	GI₅₀	30.3 μM Compound: 1	Cytotoxicity against human A2780 cells assessed as cell growth inhibition after 72 hrs by MTS assay Cytotoxicity against human A2780 cells assessed as cell growth inhibition after 72 hrs by MTS assay	[PMID: 27128175]
A2780	IC₅₀	7.77 μM Compound: 2	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 22749392]
A-431	IC₅₀	> 100 μM Compound: Tamoxifen	Cytotoxicity against human A431 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay Cytotoxicity against human A431 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay	[PMID: 29605808]
A549	IC₅₀	1.86 μg/mL Compound: Tomoxifen	Cytotoxicity against human A549 cells by alamar blue assay Cytotoxicity against human A549 cells by alamar blue assay	[PMID: 11720540]
A549	IC₅₀	10.08 μM Compound: Tamoxifen	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 31884407]
A549	IC₅₀	10.87 μM Compound: Tamoxifen	Antiproliferative activity against human A549 cells by MTT assay Antiproliferative activity against human A549 cells by MTT assay	[PMID: 31546197]
A549	IC₅₀	12 μM Compound: TAM	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 23287057]
A549	IC₅₀	17.3 μM Compound: Tamoxifen	Cytotoxicity against human A549 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay Cytotoxicity against human A549 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay	[PMID: 29605808]
A549	IC₅₀	17.3 μM Compound: Tamoxifen	Anticancer activity against human A549 cells measured after 48 hrs by SRB assay Anticancer activity against human A549 cells measured after 48 hrs by SRB assay	[PMID: 27671497]
A549	GI₅₀	24.4 μM Compound: Tamoxifen	Anti-proliferative activity against human A549 cells incubated for 48 hrs by SRB assay Anti-proliferative activity against human A549 cells incubated for 48 hrs by SRB assay	[PMID: 26163220]
A549	IC₅₀	8.4 μM Compound: Tamoxifen	Cytotoxicity against human A549 cells assessed as cell viability by MTT assay Cytotoxicity against human A549 cells assessed as cell viability by MTT assay	[PMID: 26079090]
A549	IC₅₀	9.66 μM Compound: 2	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 22749392]
Astrocyte	IC₅₀	> 10 μM Compound: Tamoxifen	Cytotoxicity against normal human astrocytes assessed as cell viability incubated for 72 hrs by WST-1 method Cytotoxicity against normal human astrocytes assessed as cell viability incubated for 72 hrs by WST-1 method	[PMID: 26355532]
B16-F10	IC₅₀	64.87 μM Compound: Tam	Antiproliferative activity mouse B16F10 cells after 2 days by MTT assay Antiproliferative activity mouse B16F10 cells after 2 days by MTT assay	[PMID: 25222876]
CHO	IC₅₀	> 100 μM Compound: Tam	Antiproliferative activity against CHO cells after 2 days by MTT assay Antiproliferative activity against CHO cells after 2 days by MTT assay	[PMID: 25222876]
DLD-1	IC₅₀	11.06 μM Compound: Tamoxifen	Anticancer activity against human DLD1 cells measured after 48 hrs by SRB assay Anticancer activity against human DLD1 cells measured after 48 hrs by SRB assay	[PMID: 27671497]
DLD-1	IC₅₀	16.3 μM Compound: Tamoxifen	Cytotoxicity against human DLD1 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay Cytotoxicity against human DLD1 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay	[PMID: 29605808]
DLD-1	IC₅₀	4.78 μM Compound: 2	Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay	[PMID: 22749392]
DU-145	IC₅₀	10.87 μM Compound: Tamoxifen	Antiproliferative activity against human DU145 cells by MTT assay Antiproliferative activity against human DU145 cells by MTT assay	[PMID: 31546197]
DU-145	IC₅₀	18.07 μM Compound: Tamoxifen	Anticancer activity against human DU145 cells measured after 48 hrs by SRB assay Anticancer activity against human DU145 cells measured after 48 hrs by SRB assay	[PMID: 27671497]
DU-145	GI₅₀	19.3 μM Compound: Tamoxifen	Anti-proliferative activity against human DU145 cells incubated for 48 hrs by SRB assay Anti-proliferative activity against human DU145 cells incubated for 48 hrs by SRB assay	[PMID: 26163220]
DU-145	IC₅₀	28.9 μM Compound: Tamoxifen	Cytotoxicity against ERalpha-deficient human DU145 cells expressing ERbeta assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against ERalpha-deficient human DU145 cells expressing ERbeta assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23786452]
DU-145	IC₅₀	5.5 μM Compound: TAM	Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay	[PMID: 23287057]
DU-145	GI₅₀	6.07 μM Compound: Tamoxifen	Anticancer activity against human DU145 cells after 24 hrs by SRB assay Anticancer activity against human DU145 cells after 24 hrs by SRB assay	[PMID: 19733085]
EKVX	GI₅₀	6.3 μM Compound: TAM	Cytotoxicity against human EKVX cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human EKVX cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26896706]
FaDu	IC₅₀	5.39 μM Compound: Tamoxifen	Anticancer activity against human FADU cells measured after 48 hrs by SRB assay Anticancer activity against human FADU cells measured after 48 hrs by SRB assay	[PMID: 27671497]
Fibroblast	IC₅₀	> 20 μM Compound: TAM	Antiproliferative activity against mouse fibroblasts after 48 hrs by MTT assay Antiproliferative activity against mouse fibroblasts after 48 hrs by MTT assay	[PMID: 23287057]
Fibroblast	CC₅₀	11.1 μM Compound: Tamoxifen	Cytotoxicity against human HSF cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HSF cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33373820]
Fibroblast	CC₅₀	12.7 μM Compound: Tamoxifen	Cytotoxicity against human HSF cells assessed as reduction in colony formation incubated for 7 days by crystal violet staining based assay Cytotoxicity against human HSF cells assessed as reduction in colony formation incubated for 7 days by crystal violet staining based assay	[PMID: 33373820]
HCT-116	IC₅₀	45 μM Compound: Tamoxifen	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 31884407]
HCT-15	GI₅₀	3.16 μM Compound: TAM	Cytotoxicity against human HCT15 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human HCT15 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26896706]
HEK293	IC₅₀	> 50 μM Compound: Tamoxifen	Cytotoxicity against HEK293 cells by MTT assay Cytotoxicity against HEK293 cells by MTT assay	[PMID: 31546197]
HEK293	IC₅₀	10 μM Compound: Tamoxifen	Cytotoxicity against HEK293 cells after 24 hrs by MTT assay Cytotoxicity against HEK293 cells after 24 hrs by MTT assay	[PMID: 20605470]
HEK293	IC₅₀	10 μM Compound: Tamoxifen	Antiproliferative activity against human HEK293 cells after 48 hrs by MTT assay Antiproliferative activity against human HEK293 cells after 48 hrs by MTT assay	[PMID: 21871812]
HEK293	CC₅₀	13 μg/mL Compound: TAM	Cytotoxicity against HEK293 cells after 24 hrs by resazurin dye-based fluorescence analysis Cytotoxicity against HEK293 cells after 24 hrs by resazurin dye-based fluorescence analysis	[PMID: 30316060]
HEK293	CC₅₀	13.1 μg/mL Compound: Tamoxifen	Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 20 hrs by resazurin dye-based fluorescence assay Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 20 hrs by resazurin dye-based fluorescence assay	[PMID: 30901686]
HEK293	CC₅₀	13.1 μg/mL Compound: Tamoxifen	Cytotoxicity against human HEK293 cells assessed as reduction in cell growth incubated for 20 hrs by resazurin dye-based fluorometric assay Cytotoxicity against human HEK293 cells assessed as reduction in cell growth incubated for 20 hrs by resazurin dye-based fluorometric assay	[PMID: 30831407]
HEK293	IC₅₀	20.93 μM Compound: Tamoxifen	Antiproliferative activity against HEK293 cells after 48 hrs by MTT assay Antiproliferative activity against HEK293 cells after 48 hrs by MTT assay	[PMID: 29054359]
HEK293	IC₅₀	22.4 μM Compound: TAM	Cytotoxicity against human HEK293 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HEK293 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 34153643]
HEK293	IC₅₀	24 μM Compound: Tamoxifen	Cytotoxicity against HEK293 cells assessed as cell growth inhibition measured after 20 hrs by resazurin dye based assay Cytotoxicity against HEK293 cells assessed as cell growth inhibition measured after 20 hrs by resazurin dye based assay	[PMID: 35477062]
HEK293	IC₅₀	24 μM Compound: Tamoxifen	Cytotoxicity against HEK293 cells measured after 20 hrs by resazurin dye based fluorescence assay Cytotoxicity against HEK293 cells measured after 20 hrs by resazurin dye based fluorescence assay	[PMID: 30975502]
HEK293	IC₅₀	26 μM Compound: TAM	Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay	[PMID: 24457094]
HEK293	IC₅₀	26.33 μM Compound: 1	Cytotoxicity against human HEK293 cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human HEK293 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 35276362]
HEK293	CC₅₀	39.4 μM Compound: Tamoxifen	Cytotoxicity against HEK293 cells after 24 hrs by resazurin dye-based fluorescence analysis Cytotoxicity against HEK293 cells after 24 hrs by resazurin dye-based fluorescence analysis	[PMID: 30322754]
HEK293	IC₅₀	50 μM Compound: Tamoxifen	Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay	[PMID: 24880230]
HEK293	CC₅₀	62 μM Compound: Tamoxifen	Cytotoxicity against HEK293 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin based assay Cytotoxicity against HEK293 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin based assay	[PMID: 28257200]
HEK293	CC₅₀	9 μg/mL Compound: Tamoxifen	Cytotoxicity against HEK293 cells assessed as cell viability after 20 hrs by fluorescence assay Cytotoxicity against HEK293 cells assessed as cell viability after 20 hrs by fluorescence assay	[PMID: 33609657]
HEK293	CC₅₀	9 μg/mL Compound: Tamoxifen	Cytotoxicity against HEK293 cells measured after 20 hrs by resazurin dye based fluorescence assay Cytotoxicity against HEK293 cells measured after 20 hrs by resazurin dye based fluorescence assay	[PMID: 32619924]
HEK293	CC₅₀	9 μg/mL Compound: Tamoxifen	Cytotoxicity against human HEK-293 cells incubated for 23 hrs by CO-ADD method Cytotoxicity against human HEK-293 cells incubated for 23 hrs by CO-ADD method	[PMID: 33738069]
HEK-293T	IC₅₀	0.039 μM Compound: Tamoxifen	Antagonist activity at Gal4 DBD-fused human ERalpha LBD expressed in HEK293T cells assessed as inhibition of estradiol-induced transcriptional activation after 20 hrs by luciferase reporter gene assay Antagonist activity at Gal4 DBD-fused human ERalpha LBD expressed in HEK293T cells assessed as inhibition of estradiol-induced transcriptional activation after 20 hrs by luciferase reporter gene assay	[PMID: 23786452]
HeLa	IC₅₀	0.341 μM Compound: Tamoxifen	Antagonist activity at full length ERalpha (unknown origin) expressed in human HeLa cells incubated for 24 hrs by ERE-driven luciferase reporter gene assay Antagonist activity at full length ERalpha (unknown origin) expressed in human HeLa cells incubated for 24 hrs by ERE-driven luciferase reporter gene assay	[PMID: 28882502]
HeLa	IC₅₀	0.73 μM Compound: Tamoxifen	Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay	[PMID: 29624387]
HeLa	IC₅₀	1.53 μM Compound: Tamoxifen	Antagonist activity at full length ERbeta (unknown origin) expressed in human HeLa cells incubated for 24 hrs by ERE-driven luciferase reporter gene assay Antagonist activity at full length ERbeta (unknown origin) expressed in human HeLa cells incubated for 24 hrs by ERE-driven luciferase reporter gene assay	[PMID: 28882502]
HeLa	IC₅₀	10.87 μM Compound: Tamoxifen	Antiproliferative activity against human HeLa cells by MTT assay Antiproliferative activity against human HeLa cells by MTT assay	[PMID: 31546197]
HeLa	GI₅₀	12 μM Compound: 1	Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by trypan blue assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by trypan blue assay	[PMID: 27128175]
HeLa	IC₅₀	12.5 μM Compound: Tamoxifen	Cytotoxicity against human HeLa cells after 24 hrs by MTT assay Cytotoxicity against human HeLa cells after 24 hrs by MTT assay	[PMID: 20605470]
HeLa	GI₅₀	32.6 μM Compound: 1	Antiproliferative activity against human HeLa cells after 72 hrs by trypan blue assay Antiproliferative activity against human HeLa cells after 72 hrs by trypan blue assay	[PMID: 23735829]
HeLa	IC₅₀	8.85 μM Compound: Tamoxifen	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 28838694]
Hepatocyte	EC₅₀	34.4 μM Compound: Tamoxifen	Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 24 hrs by ATP detection based assay Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 24 hrs by ATP detection based assay	[PMID: 22531045]
Hepatocyte	EC₅₀	67.6 μM Compound: Tamoxifen	Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 4 hrs by LDH release assay Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 4 hrs by LDH release assay	[PMID: 22531045]
Hepatocyte	EC₅₀	71.4 μM Compound: Tamoxifen	Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 4 hrs by ATP detection based assay Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 4 hrs by ATP detection based assay	[PMID: 22531045]
HepG2	IC₅₀	12 μM Compound: Tamoxifen	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 30613327]
HepG2	IC₅₀	19.6 μM Compound: Tamoxifen	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by cell-titer 96 aqueous one solution cell proliferation assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by cell-titer 96 aqueous one solution cell proliferation assay	[PMID: 34015704]
HepG2	GI₅₀	21.7 μM Compound: Tamoxifen	Anti-proliferative activity against human HepG2 cells incubated for 48 hrs by SRB assay Anti-proliferative activity against human HepG2 cells incubated for 48 hrs by SRB assay	[PMID: 26163220]
HepG2	IC₅₀	23.4 μM Compound: tamoxifen	Cytotoxicity against human HepG2 cells after 24 hrs by CellTiter-BlueCell viability assay Cytotoxicity against human HepG2 cells after 24 hrs by CellTiter-BlueCell viability assay	[PMID: 20545334]
HepG2	CC₅₀	24.7 μM Compound: Tamoxifen	Cytotoxicity against human HepG2 cells after 24 hrs by resazurin dye-based fluorescence analysis Cytotoxicity against human HepG2 cells after 24 hrs by resazurin dye-based fluorescence analysis	[PMID: 30322754]
HepG2	EC₅₀	35 μM Compound: Tamoxifen	Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 4 hrs by CellTiter-Glo assay Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 4 hrs by CellTiter-Glo assay	[PMID: 27652492]
HepG2	EC₅₀	35 μM Compound: Tamoxifen	Cytotoxicity in human HepG2 cells assessed as induction of cell necrosis incubated for 4 hrs by LDH release assay Cytotoxicity in human HepG2 cells assessed as induction of cell necrosis incubated for 4 hrs by LDH release assay	[PMID: 27652492]
HepG2	IC₅₀	6.3 μM Compound: TAM	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 23287057]
HepG2	CC₅₀	62 μM Compound: Tamoxifen	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin based assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin based assay	[PMID: 28257200]
HL-60	IC₅₀	14.3 μM Compound: Tamoxifen	Cytotoxicity against human HL60 cells after 72 hrs by WST1 assay in presence of 20% FBS Cytotoxicity against human HL60 cells after 72 hrs by WST1 assay in presence of 20% FBS	[PMID: 22901895]
HL-60	IC₅₀	5.9 μg/mL Compound: 1, Tamoxifen	Growth inhibition of human HL60 cells after 4 hrs by MTT assay Growth inhibition of human HL60 cells after 4 hrs by MTT assay	[PMID: 17904372]
HT-29	IC₅₀	1.86 μg/mL Compound: Tomoxifen	Cytotoxicity against human HT-29 cells by alamar blue assay Cytotoxicity against human HT-29 cells by alamar blue assay	[PMID: 11720540]
HT-29	IC₅₀	38.6 μM Compound: tamoxifen	Cytotoxicity against human HT-29 cells after 24 hrs by CellTiter-BlueCell viability assay Cytotoxicity against human HT-29 cells after 24 hrs by CellTiter-BlueCell viability assay	[PMID: 20545334]
Ishikawa	IC₅₀	0.42 μM Compound: tamoxifen	Antiestrogenic activity in human Ishikawa cells assessed as inhibition of estrogen-induced alkaline phosphatase activity after 4 days by ELISA Antiestrogenic activity in human Ishikawa cells assessed as inhibition of estrogen-induced alkaline phosphatase activity after 4 days by ELISA	[PMID: 9784163]
Ishikawa	IC₅₀	14.58 μM Compound: Tamoxifen	Antiproliferative activity against ER-positive human Ishikawa cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay Antiproliferative activity against ER-positive human Ishikawa cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay	[PMID: 34509864]
Ishikawa	IC₅₀	16.47 μM Compound: Tamoxifen	Antiproliferative activity against human Ishikawa cells after 48 hrs by MTT assay Antiproliferative activity against human Ishikawa cells after 48 hrs by MTT assay	[PMID: 28460819]
Ishikawa	IC₅₀	16.78 μM Compound: Tamoxifen	Antiproliferative activity against human Ishikawa cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay Antiproliferative activity against human Ishikawa cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay	[PMID: 34022716]
Ishikawa	IC₅₀	170 nM Compound: 1a	Antiestrogenic activity in human Ishikawa cells assessed as inhibition of estrogen-induced alkaline phosphatase activity after 72 hrs Antiestrogenic activity in human Ishikawa cells assessed as inhibition of estrogen-induced alkaline phosphatase activity after 72 hrs	[PMID: 18835176]
Ishikawa	IC₅₀	20.65 μM Compound: Tamoxifen	Cytotoxicity in human Ishikawa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity in human Ishikawa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 28942113]
Ishikawa	IC₅₀	22.5 μM Compound: Tamoxifen	Antiproliferative activity against human Ishikawa cells expressing estrogen receptor after 48 hrs by MTT assay Antiproliferative activity against human Ishikawa cells expressing estrogen receptor after 48 hrs by MTT assay	[PMID: 21871812]
Ishikawa	IC₅₀	26.52 μM Compound: Tamoxifen	Antiproliferative activity against human Ishikawa cells after 48 hrs by MTT assay Antiproliferative activity against human Ishikawa cells after 48 hrs by MTT assay	[PMID: 29587221]
Ishikawa	IC₅₀	6 μM Compound: Tamoxifen	Antiproliferative activity against human Ishikawa cells incubated for 48 hrs by MTT assay Antiproliferative activity against human Ishikawa cells incubated for 48 hrs by MTT assay	[PMID: 27176944]
Ishikawa	IC₅₀	7.87 μg/mL Compound: Tamoxifen	Inhibition of estradiol-induced proliferation in human Ishikawa cells after 72 hrs by Cell-titer-Glo assay Inhibition of estradiol-induced proliferation in human Ishikawa cells after 72 hrs by Cell-titer-Glo assay	[PMID: 28442256]
J774.A1	CC₅₀	11.06 μM Compound: Tamoxifen	Cytotoxicity against mouse J774A.1 cells assessed as reduction in cell viability incubated for 24 hrs by neutral red uptake assay Cytotoxicity against mouse J774A.1 cells assessed as reduction in cell viability incubated for 24 hrs by neutral red uptake assay	[PMID: 31376569]
Jurkat	IC₅₀	8.3 μM Compound: Tamoxifen	Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay	[PMID: 23792352]
K562	GI₅₀	5.2 μM Compound: tamoxifen	Antiproliferative activity against human K562 cells after 72 hrs Antiproliferative activity against human K562 cells after 72 hrs	[PMID: 25420175]
MCF-10A	IC₅₀	> 1000 μM Compound: Tamoxifen	Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 24 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 24 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis	[PMID: 36603398]
MCF-10A	IC₅₀	> 1000 μM Compound: Tamoxifen	Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis	[PMID: 36603398]
MCF-10A	IC₅₀	> 50 μM Compound: Tamoxifen	Cytotoxicity against human MCF-10A cells after 48 hrs by MTT assay Cytotoxicity against human MCF-10A cells after 48 hrs by MTT assay	[PMID: 33340662]
MCF7	IC₅₀	< 1000 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis	[PMID: 36603398]
MCF7	EC₅₀	> 200 nM Compound: 2	Antiproliferative activity against human MCF-7 cells incubated for 72 hrs by Cell-titer Glo assay Antiproliferative activity against human MCF-7 cells incubated for 72 hrs by Cell-titer Glo assay	[PMID: 34251202]
MCF7	IC₅₀	0.027 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 22472045]
MCF7	IC₅₀	0.794 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells after 5 days Cytotoxicity against human MCF7 cells after 5 days	[PMID: 23864928]
MCF7	IC₅₀	1 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells by MTT assay Antiproliferative activity against human MCF7 cells by MTT assay	[PMID: 20451380]
MCF7	IC₅₀	1.31 μg/mL Compound: Tamoxifen	Antiproliferative activity against human MCF-7 cells assessed as inhibition of colony formation measured after 3 weeks by crystal violet staining based soft agar colony formation assay Antiproliferative activity against human MCF-7 cells assessed as inhibition of colony formation measured after 3 weeks by crystal violet staining based soft agar colony formation assay	[PMID: 31884407]
MCF7	GI₅₀	1.58 μM Compound: TAM	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26896706]
MCF7	IC₅₀	1.82 μM Compound: TAMOX, TAM	Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 23123017]
MCF7	IC₅₀	1.89 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 24721727]
MCF7	EC₅₀	10 nM Compound: 3 (Tamoxifen)	Effective concentration against MCF-7 breast tumor cells using MCF-7 assay. Effective concentration against MCF-7 breast tumor cells using MCF-7 assay.	[PMID: 12825935]
MCF7	IC₅₀	10 μM Compound: tamoxifene	Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 48 hrs by MTT assay	[PMID: 19423356]
MCF7	IC₅₀	10.74 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells incubated for 72 hrs by Sulphorhodamine assay Cytotoxicity against human MCF7 cells incubated for 72 hrs by Sulphorhodamine assay	[PMID: 37146520]
MCF7	IC₅₀	10.87 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells by MTT assay Antiproliferative activity against human MCF7 cells by MTT assay	[PMID: 31546197]
MCF7	IC₅₀	10.9 μM Compound: Tamoxifen	Cytotoxicity against human adriamycin- resistant MCF7 cells by WST-1 assay Cytotoxicity against human adriamycin- resistant MCF7 cells by WST-1 assay	[PMID: 19836230]
MCF7	IC₅₀	11 μM Compound: Tamoxifen	Inhibitory concentration against MCF-7 (ER+) cell line using SRB assay Inhibitory concentration against MCF-7 (ER+) cell line using SRB assay	[PMID: 12565971]
MCF7	IC₅₀	11.1 μM Compound: Tamoxifen	Cytotoxicity against human tamoxifen-resistant MCF7 cells by WST-1 assay Cytotoxicity against human tamoxifen-resistant MCF7 cells by WST-1 assay	[PMID: 19836230]
MCF7	IC₅₀	11.35 μM Compound: Tamoxifen	Antiproliferative activity against ER positive human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against ER positive human MCF7 cells after 48 hrs by MTT assay	[PMID: 28460819]
MCF7	IC₅₀	11.4 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells by WST-1 assay Cytotoxicity against human MCF7 cells by WST-1 assay	[PMID: 19836230]
MCF7	IC₅₀	11.44 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 23022281]
MCF7	IC₅₀	11.55 μM Compound: Tamoxifen	Antiproliferative activity against human MCF-7 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Antiproliferative activity against human MCF-7 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 31884407]
MCF7	IC₅₀	11.8 μM Compound: Tamoxifen	Anticancer activity against human MCF7 cells expressing estrogen receptor by MTT assay Anticancer activity against human MCF7 cells expressing estrogen receptor by MTT assay	[PMID: 20951035]
MCF7	IC₅₀	12 μM Compound: tamoxifen	Anticancer activity against estrogen-positive human MCF7 cells after 18 hrs by MTT assay Anticancer activity against estrogen-positive human MCF7 cells after 18 hrs by MTT assay	[PMID: 19446930]
MCF7	GI₅₀	12 μM Compound: 1	Antiproliferative activity against human MCF7 cells after 72 hrs by trypan blue assay Antiproliferative activity against human MCF7 cells after 72 hrs by trypan blue assay	[PMID: 23735829]
MCF7	IC₅₀	12.35 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 23830503]
MCF7	IC₅₀	12.48 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 48 hrs by MTT assay	[PMID: 21871812]
MCF7	IC₅₀	12.5 μM Compound: Tam	Cytotoxicity against human MCF7 cells expressing ER after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells expressing ER after 48 hrs by MTT assay	10.1039/C4MD00289J
MCF7	IC₅₀	13.45 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 23902804]
MCF7	IC₅₀	13.7 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells by MTT reduction assay Antiproliferative activity against human MCF7 cells by MTT reduction assay	[PMID: 33421712]
MCF7	IC₅₀	14.35 μM Compound: Tamoxifen	Cytotoxicity in human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity in human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 28942113]
MCF7	IC₅₀	15.2 μM Compound: 6	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 23880359]
MCF7	IC₅₀	15.21 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 33340662]
MCF7	IC₅₀	15.46 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 29587221]
MCF7	IC₅₀	15.6 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells expressing ERalpha and ERbeta assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells expressing ERalpha and ERbeta assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23786452]
MCF7	IC₅₀	16.7 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 30384047]
MCF7	IC₅₀	18.18 μM Compound: Tamoxifen	Anticancer activity against human ER-positive MCF7 cells measured after 48 hrs by SRB assay Anticancer activity against human ER-positive MCF7 cells measured after 48 hrs by SRB assay	[PMID: 27671497]
MCF7	IC₅₀	18.71 μM Compound: tamoxifen	Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated at 37 degC for 3 days by resazurin microplate assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated at 37 degC for 3 days by resazurin microplate assay	[PMID: 25734623]
MCF7	IC₅₀	19.2 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by resazurin based fluorescence assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by resazurin based fluorescence assay	[PMID: 33852304]
MCF7	IC₅₀	19.33 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by resazurin microplate assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by resazurin microplate assay	[PMID: 27311894]
MCF7	IC₅₀	19.5 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 29482944]
MCF7	IC₅₀	19.54 μM Compound: Tam	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 24 hrs by MTT assay	[PMID: 22647217]
MCF7	IC₅₀	2.1 μM Compound: tamoxifen	Antiproliferative activity against human MCF7 cells after 5 days by WST-8 assay Antiproliferative activity against human MCF7 cells after 5 days by WST-8 assay	[PMID: 25614118]
MCF7	IC₅₀	20 nM Compound: 7	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 33479633]
MCF7	IC₅₀	200 nM Compound: Tamoxifen	Antagonist activity at ERalpha receptor in human MCF7 cells assessed as inhibition of cell growth after 6 days by crystal violet staining method Antagonist activity at ERalpha receptor in human MCF7 cells assessed as inhibition of cell growth after 6 days by crystal violet staining method	[PMID: 23448346]
MCF7	IC₅₀	21.57 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 28505536]
MCF7	IC₅₀	22.6 μM Compound: TAM	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31620225]
MCF7	IC₅₀	25 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7cells assessed as reduction in cell viability after 24 hrs by DAPI/propidium iodide staining based assay Antiproliferative activity against human MCF7cells assessed as reduction in cell viability after 24 hrs by DAPI/propidium iodide staining based assay	[PMID: 31673312]
MCF7	IC₅₀	25 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells by fluorescence based viable cell counting method Antiproliferative activity against human MCF7 cells by fluorescence based viable cell counting method	[PMID: 31610378]
MCF7	IC₅₀	27.96 μM Compound: 1, TAM	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 23860592]
MCF7	IC₅₀	3.8 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells assessed as cell viability by MTT assay Cytotoxicity against human MCF7 cells assessed as cell viability by MTT assay	[PMID: 26079090]
MCF7	IC₅₀	3.99 μg/mL Compound: Tamoxifen	Inhibition of estradiol-induced proliferation in human MCF7 cells after 72 hrs by Cell-titer-Glo assay Inhibition of estradiol-induced proliferation in human MCF7 cells after 72 hrs by Cell-titer-Glo assay	[PMID: 28442256]
MCF7	IC₅₀	30 nM Compound: Tam	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 6 days by SRB assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 6 days by SRB assay	[PMID: 33257172]
MCF7	IC₅₀	31 μM Compound: TEM	Cytotoxicity activity against human MCF7 cells by MTS assay Cytotoxicity activity against human MCF7 cells by MTS assay	[PMID: 21680064]
MCF7	IC₅₀	4 μM Compound: TAM	Cytotoxicity against human MCF7 Cells after 48 hrs by neutral red dye-based assay Cytotoxicity against human MCF7 Cells after 48 hrs by neutral red dye-based assay	[PMID: 31129455]
MCF7	IC₅₀	4.1 μM Compound: 2a	Antiproliferative activity against ER-dependent human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against ER-dependent human MCF7 cells after 72 hrs by MTT assay	[PMID: 28426931]
MCF7	IC₅₀	4.1 μM Compound: 2	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 25369367]
MCF7	IC₅₀	4.1 μM Compound: Tamoxifen	Antiproliferative activity against ER-positive human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by AlamarBlue assay Antiproliferative activity against ER-positive human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by AlamarBlue assay	[PMID: 27407030]
MCF7	IC₅₀	4.12 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by MTT assay	[PMID: 31987694]
MCF7	IC₅₀	4.12 μM Compound: 1a	Antiproliferative activity against estrogen receptor dependent human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against estrogen receptor dependent human MCF7 cells after 72 hrs by MTT assay	[PMID: 18835176]
MCF7	IC₅₀	4.4 μM Compound: TAM	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 26896706]
MCF7	IC₅₀	4.4 μM Compound: 2a	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 5 days by SRB assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 5 days by SRB assay	[PMID: 28426931]
MCF7	IC₅₀	4.67 μM Compound: Tam	Antiproliferative activity human ER-positive MCF7 cells after 2 days by MTT assay Antiproliferative activity human ER-positive MCF7 cells after 2 days by MTT assay	[PMID: 25222876]
MCF7	IC₅₀	42.4 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 30731397]
MCF7	ED₅₀	5 μg/mL Compound: TAM	Cytotoxicity against human MCF7 cells expressing estrogen receptor after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells expressing estrogen receptor after 72 hrs by SRB assay	[PMID: 19425534]
MCF7	IC₅₀	5.09 μM Compound: TAM	Antiproliferative activity against MCF7 cells at 3 mg/kg/day after 48 hrs Antiproliferative activity against MCF7 cells at 3 mg/kg/day after 48 hrs	[PMID: 16979337]
MCF7	IC₅₀	5.19 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells by SRB assay Cytotoxicity against human MCF7 cells by SRB assay	[PMID: 23806014]
MCF7	IC₅₀	5.3 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay	[PMID: 27176944]
MCF7	IC₅₀	5.3 μM Compound: Tamoxifen	Growth inhibition of human MCF7 cells after 72 hrs by MTT assay Growth inhibition of human MCF7 cells after 72 hrs by MTT assay	[PMID: 29220789]
MCF7	IC₅₀	5.4 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 34726897]
MCF7	IC₅₀	5.5 μM Compound: TAM	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 23287057]
MCF7	IC₅₀	5.62 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 33894490]
MCF7	IC₅₀	50 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 24 hrs by MTT assay	[PMID: 36846377]
MCF7	IC₅₀	50 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 36846377]
MCF7	IC₅₀	50 μM Compound: Tamoxifen	Cytotoxicity against human ER-positive MCF7 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human ER-positive MCF7 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26972118]
MCF7	IC₅₀	54 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 33234343]
MCF7	IC₅₀	55.5 μM Compound: Tamoxifen	Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as inhibition of cell proliferation after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as inhibition of cell proliferation after 72 hr by MTT assay	10.1007/s00044-012-0391-5
MCF7	IC₅₀	580 nM Compound: tamoxifen	Antiproliferative activity against human MCF7 cells after 24 hrs by MTS assay Antiproliferative activity against human MCF7 cells after 24 hrs by MTS assay	[PMID: 18272256]
MCF7	IC₅₀	580 nM Compound: 3 (Tamoxifen)	Inhibitory concentration against MCF-7 breast tumor cells using MCF-7 assay. Inhibitory concentration against MCF-7 breast tumor cells using MCF-7 assay.	[PMID: 12825935]
MCF7	IC₅₀	6 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 24880230]
MCF7	IC₅₀	6.3 μM Compound: Tamoxifen	Cytotoxicity against ER and PR-positive human MCF7 cells assessed as reduction in colony formation incubated for 7 days by crystal violet staining based assay Cytotoxicity against ER and PR-positive human MCF7 cells assessed as reduction in colony formation incubated for 7 days by crystal violet staining based assay	[PMID: 33373820]
MCF7	GI₅₀	6.5 μM Compound: 1	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by trypan blue assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by trypan blue assay	[PMID: 27128175]
MCF7	GI₅₀	6.8 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 120 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 120 hrs by MTT assay	[PMID: 28152429]
MCF7	IC₅₀	6.99 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells by resazurin microplate assay Cytotoxicity against human MCF7 cells by resazurin microplate assay	[PMID: 27228159]
MCF7	IC₅₀	64.3 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 25164760]
MCF7	IC₅₀	7.09 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 30360952]
MCF7	IC₅₀	7.1 μM Compound: 2	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 22749392]
MCF7	IC₅₀	7.65 μM Compound: TAM	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 19740667]
MCF7	IC₅₀	7.94 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells after 72 hrs by resazurin based fluorescence assay Cytotoxicity against human MCF7 cells after 72 hrs by resazurin based fluorescence assay	[PMID: 28927795]
MCF7	IC₅₀	8 μg/mL Compound: Tamoxifen	Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 24576797]
MCF7	GI₅₀	8 μM Compound: Tamoxifen	Anti-proliferative activity against human MCF7 cells incubated for 48 hrs by SRB assay Anti-proliferative activity against human MCF7 cells incubated for 48 hrs by SRB assay	[PMID: 26163220]
MCF7	IC₅₀	8.12 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 29054359]
MCF7	IC₅₀	8.31 μg/mL Compound: TAM	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 21115211]
MCF7	IC₅₀	8.38 μg/mL Compound: Tamoxifen	Anticancer activity against human MCF7 cells assessed a cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human MCF7 cells assessed a cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 32771798]
MCF7	IC₅₀	8.42 μM Compound: TAM	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 34153643]
MCF7	IC₅₀	8.5 μg/mL Compound: Tamoxifen	Cytotoxicity against human MCF7 cells by SRB assay Cytotoxicity against human MCF7 cells by SRB assay	[PMID: 36325400]
MCF7	IC₅₀	8.53 μM Compound: 1	Antiproliferative activity against human MCF7 cells assessed as cell viability after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 35276362]
MCF7	IC₅₀	8.6 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells after 72 hrs by WST1 assay in presence of 20% FBS Cytotoxicity against human MCF7 cells after 72 hrs by WST1 assay in presence of 20% FBS	[PMID: 22901895]
MCF7	IC₅₀	8.61 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay Cytotoxicity against human MCF7 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay	[PMID: 29605808]
MCF7	IC₅₀	8.9 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 20605470]
MCF7	IC₅₀	82.5 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 25164760]
MCF7	IC₅₀	9 μM Compound: Tamoxifen	Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 32731188]
MCF7	IC₅₀	9 μM Compound: TAM	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 24457094]
MCF7	IC₅₀	9.6 μM Compound: Tamoxifen	Cytotoxicity against ER and PR-positive human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against ER and PR-positive human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33373820]
MDA-MB-231	IC₅₀	< 1000 μM Compound: Tamoxifen	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis	[PMID: 36603398]
MDA-MB-231	IC₅₀	> 20 μM Compound: Tamoxifen	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 31884407]
MDA-MB-231	IC₅₀	> 50 μM Compound: Tamoxifen	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay	[PMID: 34022716]
MDA-MB-231	IC₅₀	> 50 μM Compound: Tamoxifen	Cytotoxicity against human ER-negative MDA-MB-231 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human ER-negative MDA-MB-231 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26972118]
MDA-MB-231	IC₅₀	0.66 μM Compound: Tamoxifen	Antiproliferative activity against human MDA-MB-231 cells by MTT assay Antiproliferative activity against human MDA-MB-231 cells by MTT assay	[PMID: 20451380]
MDA-MB-231	IC₅₀	10 μM Compound: TAM	Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 24457094]
MDA-MB-231	IC₅₀	10 μM Compound: Tamoxifen	Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 20605470]
MDA-MB-231	IC₅₀	10.11 μM Compound: TAM	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 34153643]
MDA-MB-231	IC₅₀	11.2 μM Compound: Tamoxifen	Antiproliferative activity against human MDA-MB-231 cells by MTT assay Antiproliferative activity against human MDA-MB-231 cells by MTT assay	[PMID: 31546197]
MDA-MB-231	IC₅₀	11.4 μM Compound: TAM	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 23287057]
MDA-MB-231	IC₅₀	12.4 μM Compound: Tamoxifen	Cytotoxicity against human MDA-MB-231 cells by WST-1 assay Cytotoxicity against human MDA-MB-231 cells by WST-1 assay	[PMID: 19836230]
MDA-MB-231	IC₅₀	12.41 μM Compound: Tamoxifen	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 23022281]
MDA-MB-231	IC₅₀	13.9 μM Compound: Tamoxifen	Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay	[PMID: 27176944]
MDA-MB-231	IC₅₀	14 μM Compound: Tamoxifen	Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 24880230]
MDA-MB-231	IC₅₀	14.5 μM Compound: Tamoxifen	Antiproliferative activity against human MDA-MB-231 cells by MTT reduction assay Antiproliferative activity against human MDA-MB-231 cells by MTT reduction assay	[PMID: 33421712]
MDA-MB-231	IC₅₀	14.94 μM Compound: 1	Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 35276362]
MDA-MB-231	IC₅₀	15.01 μM Compound: Tamoxifen	Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 33894490]
MDA-MB-231	GI₅₀	15.1 μM Compound: Tamoxifen	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 120 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 120 hrs by MTT assay	[PMID: 28152429]
MDA-MB-231	IC₅₀	17 μM Compound: Tamoxifen	Cytotoxicity against ERalpha and ERbeta-deficient human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against ERalpha and ERbeta-deficient human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23786452]
MDA-MB-231	IC₅₀	18.48 μM Compound: Tamoxifen	Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by Sulphorhodamine assay Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by Sulphorhodamine assay	[PMID: 37146520]
MDA-MB-231	IC₅₀	18.9 μM Compound: Tamoxifen	Antiproliferative activity against estrogen receptor-deficient human MDA-MB-231 cells expressing estrogen receptor after 48 hrs by MTT assay Antiproliferative activity against estrogen receptor-deficient human MDA-MB-231 cells expressing estrogen receptor after 48 hrs by MTT assay	[PMID: 21871812]
MDA-MB-231	IC₅₀	19 μM Compound: Tamoxifen	Inhibitory concentration against MDA-MB-231 (ER-) cell line using SRB assay Inhibitory concentration against MDA-MB-231 (ER-) cell line using SRB assay	[PMID: 12565971]
MDA-MB-231	IC₅₀	20 μM Compound: tamoxifene	Antiproliferative activity against human estrogen receptor deficient MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human estrogen receptor deficient MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 19423356]
MDA-MB-231	IC₅₀	24 μM Compound: tamoxifen	Anticancer activity against estrogen-positive human MDA-MB-231 cells after 18 hrs by MTT assay Anticancer activity against estrogen-positive human MDA-MB-231 cells after 18 hrs by MTT assay	[PMID: 19446930]
MDA-MB-231	IC₅₀	25.1 μM Compound: Tamoxifen	Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hr by MTT assay	10.1007/s00044-012-0391-5
MDA-MB-231	IC₅₀	27 μM Compound: Tam	Cytotoxicity against human ER negative MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human ER negative MDA-MB-231 cells after 48 hrs by MTT assay	10.1039/C4MD00289J
MDA-MB-231	IC₅₀	35.8 μM Compound: Tamoxifen	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 33340662]
MDA-MB-231	IC₅₀	38.97 μM Compound: Tam	Antiproliferative activity human ER-negative MDA-MB-231 cells after 2 days by MTT assay Antiproliferative activity human ER-negative MDA-MB-231 cells after 2 days by MTT assay	[PMID: 25222876]
MDA-MB-231	IC₅₀	47.1 μM Compound: Tamoxifen	Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 30360952]
MDA-MB-231	IC₅₀	5.9 μM Compound: Tamoxifen	Cytotoxicity against ER-negative human MDA-MB-231 cells assessed as reduction in colony formation incubated for 7 days by crystal violet staining based assay Cytotoxicity against ER-negative human MDA-MB-231 cells assessed as reduction in colony formation incubated for 7 days by crystal violet staining based assay	[PMID: 33373820]
MDA-MB-231	IC₅₀	64.85 μM Compound: 1, TAM	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 23860592]
MDA-MB-231	IC₅₀	69.7 μM Compound: Tamoxifen	Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs	[PMID: 33139111]
MDA-MB-231	IC₅₀	7 μM Compound: Tamoxifen	Cytotoxicity against ER-negative human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against ER-negative human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33373820]
MDA-MB-231	IC₅₀	7.85 μg/mL Compound: Tamoxifen	Inhibition of estradiol-induced proliferation in human MDA-MB-231 cells after 72 hrs by Cell-titer-Glo assay Inhibition of estradiol-induced proliferation in human MDA-MB-231 cells after 72 hrs by Cell-titer-Glo assay	[PMID: 28442256]
MDA-MB-231	IC₅₀	75 μM Compound: Tamoxifen	Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 33234343]
MDA-MB-231	IC₅₀	75 μM Compound: Tamoxifen	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 96 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 25164760]
MDA-MB-231	IC₅₀	84.6 μM Compound: Tamoxifen	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 25164760]
MDA-MB-231	IC₅₀	9.86 μM Compound: TAM	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 19740667]
MDA-MB-231	IC₅₀	9.96 μM Compound: Tamoxifen	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 29054359]
MDA-MB-435	GI₅₀	3.16 μM Compound: TAM	Cytotoxicity against human MDA-MB-435 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human MDA-MB-435 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26896706]
MDA-MB-435S	IC₅₀	5.5 μM Compound: Tamoxifen	Cytotoxicity against human MDA-MB-435S cells assessed as cell viability by MTT assay Cytotoxicity against human MDA-MB-435S cells assessed as cell viability by MTT assay	[PMID: 26079090]
MDA-MB-468	IC₅₀	14.99 μM Compound: Tam	Cytotoxicity against human ER negative MDA-MB-468 cells after 48 hrs by MTT assay Cytotoxicity against human ER negative MDA-MB-468 cells after 48 hrs by MTT assay	10.1039/C4MD00289J
MDA-MB-468	GI₅₀	2.5 μM Compound: TAM	Cytotoxicity against human MDA-MB-468 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human MDA-MB-468 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26896706]
MEL-JUSO	EC₅₀	14.6 μM Compound: TAM	Antiproliferative activity against human MelJuSo cells assessed as reduction in cell viability measured after 24 hrs by celltiter-blue assay Antiproliferative activity against human MelJuSo cells assessed as reduction in cell viability measured after 24 hrs by celltiter-blue assay	[PMID: 31099568]
M-HeLa	IC₅₀	28 μM Compound: Tamoxifen	Antiproliferative activity against human M-HeLa cells assessed as reduction in cell viability after 24 hrs by DAPI/propidium iodide staining based assay Antiproliferative activity against human M-HeLa cells assessed as reduction in cell viability after 24 hrs by DAPI/propidium iodide staining based assay	[PMID: 31673312]
M-HeLa	IC₅₀	28 μM Compound: Tamoxifen	Antiproliferative activity against human M-HeLa cells by fluorescence based viable cell counting method Antiproliferative activity against human M-HeLa cells by fluorescence based viable cell counting method	[PMID: 31610378]
MIA PaCa-2	IC₅₀	33.12 μM Compound: Tam	Antiproliferative activity human MIAPaCa2 cells after 2 days by MTT assay Antiproliferative activity human MIAPaCa2 cells after 2 days by MTT assay	[PMID: 25222876]
MOLT-4	GI₅₀	2.5 μM Compound: TAM	Cytotoxicity against human MOLT4 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human MOLT4 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26896706]
MRC5	CC₅₀	10 μM Compound: Tamoxifen	Cytotoxicity against human MRC5 cells measured after 7 days by MTT assay Cytotoxicity against human MRC5 cells measured after 7 days by MTT assay	[PMID: 33667089]
MRC5	IC₅₀	10.9 μM Compound: TAM	Cytotoxicity against human MRC5 cells assessed as cell viability after 4 to 7 days by Alamar Blue staining based fluorometric analysis Cytotoxicity against human MRC5 cells assessed as cell viability after 4 to 7 days by Alamar Blue staining based fluorometric analysis	[PMID: 26922226]
MRC5	IC₅₀	11.09 μM Compound: Tamoxifen	Cytotoxicity in human MRC5 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin-based cytotoxicity assay Cytotoxicity in human MRC5 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin-based cytotoxicity assay	[PMID: 30879839]
MRC5	CC₅₀	11.09 μM Compound: Tamoxifen	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability measured after 24 hrs by resazurin dye based fluorimetric assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability measured after 24 hrs by resazurin dye based fluorimetric assay	[PMID: 30857749]
MRC5	IC₅₀	11.09 μM Compound: Tamoxifen	Cytotoxicity against human MRC5 cells after 24 hrs by resazurin dye based assay Cytotoxicity against human MRC5 cells after 24 hrs by resazurin dye based assay	[PMID: 30692024]
MRC5	IC₅₀	17.2 μM Compound: Tamoxifen	Cytotoxicity against human MRC5 cells assessed as inhibition of cell growth measured after 72 hrs by resazurin staining based microscopic analysis Cytotoxicity against human MRC5 cells assessed as inhibition of cell growth measured after 72 hrs by resazurin staining based microscopic analysis	[PMID: 36242986]
MSTO-211H	GI₅₀	23.3 μM Compound: 1	Antiproliferative activity against human MSTO-211H cells after 72 hrs by trypan blue assay Antiproliferative activity against human MSTO-211H cells after 72 hrs by trypan blue assay	[PMID: 23735829]
NCI/ADR-RES	IC₅₀	11.13 μM Compound: Tamoxifen	Cytotoxicity against human MCF7/ADR cells after 48 hrs by MTT assay Cytotoxicity against human MCF7/ADR cells after 48 hrs by MTT assay	[PMID: 23022281]
NCI-H460	GI₅₀	4.48 μM Compound: Tamoxifen	Anticancer activity against human NCI-H460 cells after 24 hrs by SRB assay Anticancer activity against human NCI-H460 cells after 24 hrs by SRB assay	[PMID: 19733085]
NIH3T3	IC₅₀	> 100 μM Compound: Tam	Antiproliferative activity mouse NIH/3T3 cells after 2 days by MTT assay Antiproliferative activity mouse NIH/3T3 cells after 2 days by MTT assay	[PMID: 25222876]
NIH3T3	IC₅₀	11.4 μM Compound: TAM	Antiproliferative activity against mouse NIH/3T3 cells after 48 hrs by MTT assay Antiproliferative activity against mouse NIH/3T3 cells after 48 hrs by MTT assay	[PMID: 23287057]
NIH3T3	IC₅₀	7.26 μM Compound: 2	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 22749392]
OVCAR-5	GI₅₀	32 μM Compound: 1	Cytotoxicity against human OVCAR5 cells assessed as cell growth inhibition after 72 hrs by MTS assay Cytotoxicity against human OVCAR5 cells assessed as cell growth inhibition after 72 hrs by MTS assay	[PMID: 27128175]
PC-3	IC₅₀	> 1000 nM Compound: 7	Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 33479633]
PC-3	IC₅₀	10 μM Compound: TAM	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 23287057]
PC-3	IC₅₀	15.8 μM Compound: TAM	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 34153643]
PC-3	IC₅₀	7 μM Compound: Tamoxifen	Antiproliferative activity against human PC3 cells after 24 hrs by MTT assay Antiproliferative activity against human PC3 cells after 24 hrs by MTT assay	[PMID: 24880230]
RAW264.7	CC₅₀	11.1 μM Compound: Tamoxifen	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs by neutral red dye based assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs by neutral red dye based assay	[PMID: 31703818]
RAW264.7	IC₅₀	18.5 μM Compound: Tamoxifen	Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell growth measured after 72 hrs by resazurin staining based microscopic analysis Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell growth measured after 72 hrs by resazurin staining based microscopic analysis	[PMID: 36242986]
SH-SY5Y	IC₅₀	20 μM Compound: Tamoxifen	Inhibition of PKC in human SH-SY5Y cells assessed as inhibition of PMA-stimulated MARCKS phosphorylation preincubated for 1 hr followed by PMA-stimulation for 15 mins by Western blot analysis Inhibition of PKC in human SH-SY5Y cells assessed as inhibition of PMA-stimulated MARCKS phosphorylation preincubated for 1 hr followed by PMA-stimulation for 15 mins by Western blot analysis	[PMID: 27647375]
SK-BR-3	IC₅₀	< 1000 μM Compound: Tamoxifen	Antiproliferative activity against human SK-BR-3 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis Antiproliferative activity against human SK-BR-3 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis	[PMID: 36603398]
SK-BR-3	GI₅₀	12.5 μM Compound: Tamoxifen	Cytotoxicity against human SKBR3 cells assessed as growth inhibition after 120 hrs by MTT assay Cytotoxicity against human SKBR3 cells assessed as growth inhibition after 120 hrs by MTT assay	[PMID: 28152429]
SK-BR-3	IC₅₀	28.32 μM Compound: Tamoxifen	Cytotoxicity against human SK-BR-3 cells after 48 hrs by MTT assay Cytotoxicity against human SK-BR-3 cells after 48 hrs by MTT assay	[PMID: 33340662]
SK-BR-3	ED₅₀	5 μg/mL Compound: TAM	Cytotoxicity against estrogen receptor deficient human SKBR3 cells overexpressing human epidermal growth factor receptor 2 after 72 hrs by SRB assay Cytotoxicity against estrogen receptor deficient human SKBR3 cells overexpressing human epidermal growth factor receptor 2 after 72 hrs by SRB assay	[PMID: 19425534]
SK-MEL-28	IC₅₀	1.86 μg/mL Compound: Tomoxifen	Cytotoxicity against human SK-MEL-28 cells by alamar blue assay Cytotoxicity against human SK-MEL-28 cells by alamar blue assay	[PMID: 11720540]
SK-OV-3	GI₅₀	10 μM Compound: TAM	Cytotoxicity against human SKOV3 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human SKOV3 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26896706]
SK-OV-3	GI₅₀	6.4 μM Compound: Tamoxifen	Anticancer activity against human SKOV3 cells after 24 hrs by SRB assay Anticancer activity against human SKOV3 cells after 24 hrs by SRB assay	[PMID: 19733085]
SNB-75	GI₅₀	5.01 μM Compound: TAM	Cytotoxicity against human SNB75 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human SNB75 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26896706]
T47D	IC₅₀	0.1 μM Compound: Tamoxifen	Antiestrogenic activity in human T47D cells expressing estrogen receptor assessed as estrogen-dependent transcription by luciferase reporter gene assay Antiestrogenic activity in human T47D cells expressing estrogen receptor assessed as estrogen-dependent transcription by luciferase reporter gene assay	[PMID: 19131248]
T47D	IC₅₀	1 μM Compound: Tamoxifen	Growth inhibition of human estrogen-dependent T47D cells after 72 hrs Growth inhibition of human estrogen-dependent T47D cells after 72 hrs	[PMID: 19131248]
T47D	IC₅₀	1.13 μM Compound: Tamoxifen	Cytotoxicity against human T47D cells after 5 days Cytotoxicity against human T47D cells after 5 days	[PMID: 23864928]
T47D	GI₅₀	1.99 μM Compound: TAM	Cytotoxicity against human T47D cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human T47D cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26896706]
T47D	GI₅₀	10.6 μM Compound: Tamoxifen	Cytotoxicity against human T47D cells assessed as growth inhibition after 120 hrs by MTT assay Cytotoxicity against human T47D cells assessed as growth inhibition after 120 hrs by MTT assay	[PMID: 28152429]
T47D	IC₅₀	12.1 μM Compound: Tamoxifen	Cytotoxicity against Homo sapiens (human) T47D cells assessed as inhibition of cell proliferation after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) T47D cells assessed as inhibition of cell proliferation after 72 hr by MTT assay	10.1007/s00044-012-0391-5
T47D	IC₅₀	13 μM Compound: TAM	Antiproliferative activity against human T47D cells after 48 hrs by MTT assay Antiproliferative activity against human T47D cells after 48 hrs by MTT assay	[PMID: 23287057]
T47D	IC₅₀	14.2 μM Compound: Tamoxifen	Antiproliferative activity against human T47D cells by MTT reduction assay Antiproliferative activity against human T47D cells by MTT reduction assay	[PMID: 33421712]
T47D	IC₅₀	29.9 μM Compound: Tam	Cytotoxicity against human T47D cells expressing ER after 48 hrs by MTT assay Cytotoxicity against human T47D cells expressing ER after 48 hrs by MTT assay	10.1039/C4MD00289J
T47D	IC₅₀	34.42 μM Compound: Tamoxifen	Antiproliferative activity against human T47D cells after 24 hrs by MTT assay Antiproliferative activity against human T47D cells after 24 hrs by MTT assay	[PMID: 30731397]
THP-1	IC₅₀	11.91 μM Compound: Tamoxifen	Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 31884407]
UO-31	GI₅₀	6.3 μM Compound: TAM	Cytotoxicity against human UO31 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human UO31 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26896706]
Vero	IC₅₀	15.9 μM Compound: Tamoxifen	Cytotoxicity against african green monkey Vero cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23786452]
Vero	IC₅₀	36.2 μM Compound: Tamoxifen	Cytotoxicity against african green monkey Vero cells incubated for 72 hrs by Sulphorhodamine assay Cytotoxicity against african green monkey Vero cells incubated for 72 hrs by Sulphorhodamine assay	[PMID: 37146520]
Vero	IC₅₀	5.7 μM Compound: Tamoxifen	Cytotoxicity against African green monkey Vero cells assessed as cell viability by MTT assay Cytotoxicity against African green monkey Vero cells assessed as cell viability by MTT assay	[PMID: 26079090]

体外研究
(In Vitro)

Tamoxifen (ICI 47699) 对 MCF-7 细胞 (EC₅₀=1.41 μM) 表现出强烈的抑制作用，对 T47D 细胞 (EC₅₀=2.5 μM) 的抑制作用较小，但不影响 MDA-MB-231 细胞^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Tamoxifen可诱导肾病综合症模型和肝损伤模型。Tamoxifen 在雄性 Sprague-Dawley 大鼠中 (体重295-340g)，静脉注射 Tamoxifen (10 mg/kg) 后的药代动力学数据显示：最大血浆浓度达 1566 ng/mL，0 至 24 小时的血浆浓度-时间曲线下面积为 4757 ng·h/mL，而 0 至 1 小时的相应面积为 5006 ng·h/mL，药物的半衰期为 5.8 小时^[8]^[10]。

诱导肝损伤模型^[8]^[9]

致病原理

Tamoxifen 会降低己糖单磷酸旁路，从而增加大鼠肝细胞中氧化应激的发生率，导致肝脏损伤。

具体造模方法：

大鼠：白化病大鼠 • 雌性 • 处理 7 天
给药方式：45 mg/kg • 腹腔注射 • 每天一次，连续 7 天

Note

(1) 大鼠处于标准的实验室环境下，即 12 小时光照/12 小时黑暗循环，温度保持在 25 ± 2°C，且可以自由获取食物和水。
(2) 实验结束后，动物在轻度乙醚麻醉下通过颈椎脱位处死。将血液样本收集在肝素化的离心管中，离心得到血清。剖开腹部，立即解剖取出肝脏，用冰冷的等渗盐水洗涤，并在两张滤纸之间吸干。肝脏用铝箔包裹，在-80℃下保存。使用超声仪在冰冷的0.1 M 磷酸钾缓冲液（PH 7.5）中制备10%（w/v）的肝匀浆。

造模成功指标

分子变化：抗氧化酶(谷胱甘肽S转移酶、谷胱甘肽过氧化物酶和过氧化氢酶) 活性显著 ↓，还原型谷胱甘肽含量 ↓，同时硫代巴比妥酸反应物质(TBARS) 和肝脏转氨酶(血清谷丙转氨酶sGPT 和血清谷草转氨酶sGOT) 水平显著 ↑。

相关产品： /

拮抗产品： /

诱导 Cre 重组^[8]^[3]

致病原理

MerCreMer 小鼠是一种表达Cre 重组酶蛋白，且该蛋白与两个突变型雌激素受体配体结合域(Mer) 融合的小鼠。在没有Tamoxifen 的诱导下，Cre 重组酶处于无活性状态，当 Tamoxifen 诱导后，Tamoxifen 的代谢产物 4-OHT (雌激素类似物) 与Mer 结合，发挥 Cre 重组酶活性，进而实现基因敲除。

具体造模方法：

小鼠：转基因小鼠 • 成年 (6 周龄)
给药方式：75 mg/kg • 腹腔注射 • 每天一次，连续 5 天

Note

取经 Tamoxifen 或生理盐水盐处理的对照小鼠心脏，用磷酸盐缓冲盐水逆行灌注主动脉、左心室和冠状血管 2 分钟，然后在室温下用 X-gal 染色溶液灌注过夜，以检测整个心脏 lacZ 的活性。

造模成功指标

组织学改变：左右心室和心房中都表现出了 lacZ 染色，尽管由于心房壁较薄，心房染色看起来不太明显。
心肌细胞均表现出 lacZ 活性。
心脏中的重组率升高，重组率为 70%。

相关产品： 4-Hydroxytamoxifen (HY-16950)

拮抗产品： /

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Aldh1l1-cre/ERT2 x Ai95 mice^[3]
Dosage:	75 mg/kg
Administration:	Injected for 5 days at 6 weeks of age
Result:	Resulted in the excision of the floxed exon and a gene knockout.

Clinical Trial

分子量

371.51

Formula

C₂₆H₂₉NO

CAS 号

10540-29-1

性状

固体

颜色

White to off-white

中文名称

他莫昔芬；三苯氧胺；它莫西芬

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据

细胞实验：

Ethanol 中的溶解度 : 50 mg/mL (134.59 mM; 超声助溶)

DMSO 中的溶解度 : 25 mg/mL (67.29 mM; 超声助溶 (<60°C); 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.6917 mL	13.4586 mL	26.9172 mL
5 mM	0.5383 mL	2.6917 mL	5.3834 mL
10 mM	0.2692 mL	1.3459 mL	2.6917 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (5.60 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (5.60 mM); 悬浊液; 超声助溶

此方案可获得 2.08 mg/mL的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (5.60 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

以下溶解方案，请直接配制工作液。建议现用现配，在短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

请依序添加每种溶剂： Corn Oil
Solubility: 40 mg/mL (107.67 mM); 澄清溶液; 超声助溶

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.92%

选择批次：

Data Sheet (695 KB) SDS (701 KB)

COA (286 KB) LCMS (112 KB) 元素分析报告 (209 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998 Nov 26;339(22):1609-18. [Content Brief]

[2]. Hawariah A, et al. In vitro response of human breast cancer cell lines to the growth-inhibitory effects of styrylpyrone derivative (SPD) and assessment of its antiestrogenicity. Anticancer Res. 1998 Nov-Dec;18(6A):4383-6. [Content Brief]

[3]. Jun Nagai, et al. Hyperactivity with Disrupted Attention by Activation of an Astrocyte Synaptogenic Cue. Cell. 2019 May 16;177(5):1280-1292.e20. [Content Brief]

[4]. Zhao R, et al. Tamoxifen enhances the Hsp90 molecular chaperone ATPase activity. PLoS One. 2010 Apr 1;5(4):e9934. [Content Brief]

[5]. Kedjouar B, et al. Molecular characterization of the microsomal tamoxifen binding site. J Biol Chem. 2004 Aug 6;279(32):34048-61. [Content Brief]

[6]. Feil S, et, al. Inducible Cre mice. Methods Mol Biol. 2009;530:343-63. [Content Brief]

[7]. Laura Cooper, et al. Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors. J Med Chem. 2020 Sep 4. [Content Brief]

[8]. Sohal DS, et al. Temporally regulated and tissue-specific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein. Circ Res. 2001 Jul 6;89(1):20-5. [Content Brief]

Tamoxifen 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO / Ethanol	1 mM	2.6917 mL	13.4586 mL	26.9172 mL	67.2929 mL
	5 mM	0.5383 mL	2.6917 mL	5.3834 mL	13.4586 mL
	10 mM	0.2692 mL	1.3459 mL	2.6917 mL	6.7293 mL
	15 mM	0.1794 mL	0.8972 mL	1.7945 mL	4.4862 mL
	20 mM	0.1346 mL	0.6729 mL	1.3459 mL	3.3646 mL
	25 mM	0.1077 mL	0.5383 mL	1.0767 mL	2.6917 mL
	30 mM	0.0897 mL	0.4486 mL	0.8972 mL	2.2431 mL
	40 mM	0.0673 mL	0.3365 mL	0.6729 mL	1.6823 mL
	50 mM	0.0538 mL	0.2692 mL	0.5383 mL	1.3459 mL
	60 mM	0.0449 mL	0.2243 mL	0.4486 mL	1.1215 mL
Ethanol	80 mM	0.0336 mL	0.1682 mL	0.3365 mL	0.8412 mL
Ethanol	100 mM	0.0269 mL	0.1346 mL	0.2692 mL	0.6729 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

Tamoxifen (Synonyms: 他莫昔芬; ICI 47699; (Z)-Tamoxifen; trans-Tamoxifen)

Customer Review

Other Forms of Tamoxifen:

MCE 顾客使用本产品发表的 119 篇科研文献

Tamoxifen 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Estrogen Receptor/ERR 亚型特异性产品:

查看 HSP 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Tamoxifen 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Tamoxifen (Synonyms: 他莫昔芬; ICI 47699; (Z)-Tamoxifen; trans-Tamoxifen)

Customer Review

Other Forms of Tamoxifen:

Tamoxifen 相关抗体

MCE 顾客使用本产品发表的 119 篇科研文献

Tamoxifen 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Estrogen Receptor/ERR 亚型特异性产品:

查看 HSP 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

Tamoxifen 相关抗体:

摩尔计算器

稀释计算器

Tamoxifen 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z